Executive Editor & Producer at Blue Ice Publishing: Scientist, Adventurer, Explorer of cool things in cancer research
Kicking KRAS to the kerb It's not so long ago when we saw numerous companies vying to to drug targets such as VEGF and EGFR – with limited success in many cases. Even today there are not too many approved drugs in these two categories relative to the number of agents which ended up in 'dog drug heaven'. The dreaded phrase was originally coined by Dr Pat LoRosso while at Karmanos Cancer Centre in Detroit; she's now at Yale and the incoming AACR President. Befitting the lady's style – she's one of the nicest and kindest oncologists I've ever met – it seems a much more pleasant way to describe abandoned or discontinued anticancer agents than referring to the veritable dustbin of failed dreams. The latest posse of drugs needing some stringent culling or shakeout will likely come from the KRAS niche because the market is unlikely to be forgiving commercially of any drug not moving the needle in a substantial fashion. The good news is there are some gems in the rough for those who care to look more carefully and closely at what's needed to move forward. One of them is the focus of our latest company interview from AACR – what are Frontier Medicines doing differently and why does it matter? In an interview with their CSO, Dr Kevin Webster, we learn more about their innovative approach to tackling KRAS G12C... Check it out! https://bit.ly/49AXKGn
